Turkey's Abdi Ibrahim Beats Multinationals On Domestic Pharma Market
The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.
You may also be interested in...
Late payment of hospital debts continues to haunt the Turkish medtech industry, which recently led a public demonstration in Ankara to focus the government’s attention on the issue. Medtech multinationals fear that the ongoing problems will mean Turkey losing the positive momentum it achieved during the pandemic.
One Hurdle After Another: Safely Aligned With EU MDR, Turkish Medtechs Brace For New Efforts On Domestic Front
Alignment with the MDR gave Turkish medtech access to the EU market, but in domestic pricing, costs, reimbursement and payment of hospital debts, industry might feel it is barely at the starting line.
The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.